Literature DB >> 22723124

Bone density testing intervals and common sense.

E Michael Lewiecki1, Neil Binkley.   

Abstract

Measurement of bone mineral density (BMD) is underutilized, contributing to the underdiagnosis and undertreatment of osteoporosis. Appropriate patient selection for BMD testing leads to more people being treated, fewer fractures, and a decrease in fracture-related health care costs. Although there are well-established indications for BMD testing, it is less clear when a BMD test should be repeated for a patient who does not have osteoporosis and is found to be at low fracture risk with initial testing. BMD testing intervals should be individualized according to the likelihood that the results will influence treatment decisions.

Entities:  

Mesh:

Year:  2012        PMID: 22723124     DOI: 10.1007/s11914-012-0111-6

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  17 in total

1.  Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Authors:  Smita Nayak; Mark S Roberts; Susan L Greenspan
Journal:  Ann Intern Med       Date:  2011-12-06       Impact factor: 25.391

2.  Screening for osteoporosis in postmenopausal women: recommendations and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

3.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference.

Authors:  Sanford Baim; Neil Binkley; John P Bilezikian; David L Kendler; Didier B Hans; E Michael Lewiecki; Stuart Silverman
Journal:  J Clin Densitom       Date:  2008 Jan-Mar       Impact factor: 2.617

4.  The association of radiographically detected vertebral fractures with back pain and function: a prospective study.

Authors:  M C Nevitt; B Ettinger; D M Black; K Stone; S A Jamal; K Ensrud; M Segal; H K Genant; S R Cummings
Journal:  Ann Intern Med       Date:  1998-05-15       Impact factor: 25.391

Review 5.  Monitoring pharmacological therapy for osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Rev Endocr Metab Disord       Date:  2010-12       Impact factor: 6.514

6.  Identification of osteopenic women at high risk of fracture: the OFELY study.

Authors:  Elisabeth Sornay-Rendu; Françoise Munoz; Patrick Garnero; François Duboeuf; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2005-06-20       Impact factor: 6.741

7.  Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years.

Authors:  E D Newman; W T Ayoub; R H Starkey; J M Diehl; G C Wood
Journal:  Osteoporos Int       Date:  2003-02-18       Impact factor: 4.507

Review 8.  Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice.

Authors:  Lionel S Lim; Laura J Hoeksema; Kevin Sherin
Journal:  Am J Prev Med       Date:  2009-04       Impact factor: 5.043

9.  Cost effectiveness of screen-and-treat strategies for low bone mineral density: how do we screen, who do we screen and who do we treat?

Authors:  John T Schousboe
Journal:  Appl Health Econ Health Policy       Date:  2008       Impact factor: 2.561

10.  Axial and appendicular bone density predict fractures in older women.

Authors:  D M Black; S R Cummings; H K Genant; M C Nevitt; L Palermo; W Browner
Journal:  J Bone Miner Res       Date:  1992-06       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.